60 Degrees Pharma enters 12-month option for castanospermine license with Florida State

60 DEGREES PHARMACEUTICALS, INC.

Entered exclusive 12-month option to negotiate a royalty-bearing license for castanospermine purification technology.
Company holds 8.8 kg of Australian Chestnut extract inventory for potential botanical product commercialization.
Castanospermine is a bioactive alkaloid; company already owns IP on synthetic derivative celgosivir for viral diseases.
Company states the option agreement is not material to its business or operations.
Intends to explore non-prescription botanical extracts under changing U.S. regulatory framework.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.